menu search

PRTA / Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike

Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike
Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY. Read More
Posted: Nov 3 2023, 12:47
Author Name: Zacks Investment Research
Views: 121337

PRTA News  

Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike

By Zacks Investment Research
November 3, 2023

Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike

Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY. more_horizontal

Prothena (PRTA) Beats Q3 Earnings and Revenue Estimates

By Zacks Investment Research
November 2, 2023

Prothena (PRTA) Beats Q3 Earnings and Revenue Estimates

Prothena (PRTA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares more_horizontal

Prothena (PRTA) Soars 18.7%: Is Further Upside Left in the Stock?

By Zacks Investment Research
October 17, 2023

Prothena (PRTA) Soars 18.7%: Is Further Upside Left in the Stock?

Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the more_horizontal

Prothena shares buoyed by sale rumors

By Proactive Investors
October 16, 2023

Prothena shares buoyed by sale rumors

Shares of Prothena Corporation (NASDAQ:PRTA) added almost 25% on rumours the biotechnology firm is exploring a sale ahead of the release of key data f more_horizontal

Prothena prepares for potential sale - Bloomberg News

By Reuters
October 16, 2023

Prothena prepares for potential sale - Bloomberg News

Biotech firm Prothena Corp is preparing for a potential sale, Bloomberg News reported on Monday, citing people with knowledge of the matter. more_horizontal

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

By Seeking Alpha
September 21, 2023

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

Prothena Corporation is a protein dysregulation specialist with a focus on developing drugs for Alzheimer's disease. The company's lead candidate, PRX more_horizontal

Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why

By Zacks Investment Research
September 7, 2023

Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why

Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates. more_horizontal

Prothena (PRTA) Q2 Earnings and Revenues Miss Estimates

By Zacks Investment Research
August 4, 2023

Prothena (PRTA) Q2 Earnings and Revenues Miss Estimates

Prothena (PRTA) reports a wider-than-expected loss in the second quarter. The company makes considerable pipeline progress and updates 2023 bottom-lin more_horizontal


Search within

Pages Search Results: